Acquirement of Clinical and Genomic Data to Diagnose in Rare Inherited Cardiomyopathy

"Study Design The investigator will collect data from patients diagnosed with cardiomyopathy and will utilize secondary, real-world patient data obtained from electronic medical records at participating institutions. Study Methods 1. Blood samples will be collected after obtaining informed consent from eligible patients during outpatient visits or hospitalization. Informed consent will be obtained in a private setting to ensure patient confidentiality, with sufficient explanation provided. The study will follow standard diagnostic and treatment guidelines commonly applied to heart failure patients in Korea. Demographic information, clinical characteristics, imaging data (echocardiography, cardiac MRI), laboratory findings, and cardiovascular events will be documented separately using a case report form. 2. Following informed consent, approximately 5-10 mL of whole blood will be drawn on the same day or during the subsequent outpatient visit. The sample will be transported to SCL on the day of collection, where plasma and buffy coat will be separated and stored. 3. Genomic, laboratory, and imaging data will be integrated for comprehensive statistical analysis. 4. All study data will be stored on password-protected computers with restricted access. No personal identifiers will be included to ensure data confidentiality."